ArticleProceedings of the National Academy of Sciences of the United States of America2018
Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 75 citations in OpenAlex.
- Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer.Genome research · 2026Article
- In vivo CRISPR screening links NFKB1 to endocrine resistance in ER+ breast cancer.Endocrine-related cancer · 2026Article
- Metastasis of triple negative breast cancer is regulated by a targetable miR-342-E2F network.EMBO molecular medicine · 2026Article
- Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer.bioRxiv : the preprint server for biology · 2026Article
- Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling.Nature communications · 2026Article
- More than alternative estrogen receptors: the emerging role of GPER-1 and ERα36 in breast cancer.Exploration of targeted anti-tumor therapy · 2026Review
- Identification of a nuclear transcriptional module associated with ERα and E2F/FOXM1 signaling across PAM50 breast cancer subtypes.Frontiers in oncology · 2026Article
- Reference-guided computational framework identifies microenvironment metabolic subtypes and targets using pan-cancer single-cell datasets.Genome medicine · 2025Article
- A Reporter Platform to Study Therapy-Induced Senescence in Live Cancer Cells.Small methods · 2025Article
- METTL3-dependent m6A RNA methylation suppresses aberrant mammary epithelial differentiation and neoplastic transformation.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- CRISPR screening approaches in breast cancer research.Cancer metastasis reviews · 2025Review
- ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer.Cell reports · 2024Article
- Regulation of Cancer Metastasis by PAK2.International journal of molecular sciences · 2024Review
- Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer.Nature communications · 2024Article
- Recent advances in lung cancer organoid (tumoroid) research (Review).Experimental and therapeutic medicine · 2024Review
- SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2- breast cancer.Cell death & disease · 2024Article
- CRISPR-Cas13d screens identify KILR, a breast cancer risk-associated lncRNA that regulates DNA replication and repair.Molecular cancer · 2024Article
- The progressive trend of modeling and drug screening systems of breast cancer bone metastasis.Journal of biological engineering · 2024Review
- An estrogen-regulated long non-coding RNA NCALD promotes luminal breast cancer proliferation by activating GRHL2.Cancer cell international · 2024Article
- Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles.Molecular therapy. Methods & clinical development · 2023Article
Corrections and comments
- Commented on by
Authors and funding
21 authors at 8 institutions in 3 countries.
Tengfei XiaoCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
Wei LiCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
Xiaoqing WangCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
Han XuCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
Jixin YangCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
Qiu WuSchool of Life Science and Technology, Tongji University, Shanghai 200092, China.
Ying HuangDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Joseph GeradtsDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Peng JiangCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
Teng FeiCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
David ChiCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
Chongzhi ZangCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
Qi LiaoDepartment of Prevention Medicine, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, China.
Jonathan RennhackDepartment of Physiology, Michigan State University, East Lansing, MI 48864.
Eran AndrechekDepartment of Physiology, Michigan State University, East Lansing, MI 48864.
Nanlin LiDepartment of Vascular and Endocrine Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Simone DetreBreast Cancer Now Research Centre, The Institute of Cancer Research, London SW7 3RP, United Kingdom.
Mitchell DowsettBreast Cancer Now Research Centre, The Institute of Cancer Research, London SW7 3RP, United Kingdom.
Rinath M JeselsohnCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
X Shirley LiuCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215; xsliu@jimmy.harvard.edu myles_brown@dfci.harvard.edu.
Myles BrownCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215; xsliu@jimmy.harvard.edu myles_brown@dfci.harvard.edu.
Dana-Farber Cancer Institute · USHarvard University · USInstitute of Cancer Research · GBMichigan State University · USNingbo University · CNNortheastern University · CNTongji University · CNXijing Hospital · CN
Funding
Use of Organotypic and Mammary Gland Models to Investigate the Outcomes of ClonalP01CA080111 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI POLYAK, KORNELIA · 1999 to 2018
$36.0MLarge-Scale In Vivo Functional Characterization of the Human CistromeR01HG008728 · NHGRI · DANA-FARBER CANCER INST · PI BROWN, MYLES A, LIU, XIAOLE SHIRLEY · 2015 to 2017
$2.2MDeveloping Informatics Technologies to Model Cancer Gene RegulationU01CA180980 · NCI · DANA-FARBER CANCER INST · PI LIU, XIAOLE SHIRLEY · 2013 to 2015
$1.1MElucidating and overcoming endocrine resistance driven by ESR1 mutationsK08CA191058 · NCI · DANA-FARBER CANCER INST · PI JESELSOHN, RINATH M. · 2015 to 2019
$886kQuantitative Modeling for Chromatin Regulation of Gene Expression in CancerK22CA204439 · NCI · UNIVERSITY OF VIRGINIA · PI ZANG, CHONGZHI · 2017 to 2019
$577kThe Role of E2F2 in HER2 Positive Breast CancerF99CA212221 · NCI · MICHIGAN STATE UNIVERSITY · PI RENNHACK, JONATHAN · 2016 to 2017
$85kDepartment of HealthHSRD VA IIR 16-018NCI NIH HHS F99 CA212221NCI NIH HHS K08 CA191058NCI NIH HHS K22 CA204439NCI NIH HHS P01 CA080111NCI NIH HHS U01 CA180980NHGRI NIH HHS R01 HG008728
Abstract
Endocrine therapy resistance invariably develops in advanced estrogen receptor-positive (ER
Indexed as
Breast NeoplasmsCSK Tyrosine-Protein KinaseEstrogensFemaleGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHumansMCF-7 CellsNeoplasm Proteinsp21-Activated KinasesReceptors, Estrogensrc-Family KinasesCSK protein, humanCSK Tyrosine-Protein KinaseEstrogensNeoplasm Proteinsp21-Activated KinasesPAK2 protein, humanReceptors, Estrogensrc-Family Kinasesbreast cancerCRISPR screenCSKendocrine resistanceestrogen receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.